Patient-level predictors of achieving early glycaemic control in Type 2 diabetes mellitus: a population-based study

Diabetic Medicine

Volumn 33, Issue 11, 2016, Pages 1516-1523

  Svensson, E ^a   Baggesen, L M ^a   Thomsen, R W ^a   Lyngaa, T ^a   Pedersen, L ^a   Norrelund H ^a   Buhl, E S ^b   Haase, C L ^b   Johnsen, S P ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; DENMARK; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRESCRIPTION; RISK FACTOR; AGED; BLOOD; GLUCOSE BLOOD LEVEL; METABOLISM; REGISTER; TIME FACTOR;

ADULT; AGED; BLOOD GLUCOSE; COHORT STUDIES; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; TIME FACTORS;

EID: 84979762847     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13184     Document Type: Article

References (30)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
3. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; 11: CD008143.
4. Standards of medical care in diabetes. Diabetes Care 2004; 27 (Suppl. 1): S15–S35.
5. Standards of medical care in diabetes–2014. Diabetes Care 2014; 37 (Suppl. 1): S14–80.
6. Garber AJ, Newcomer JW, Hennekens CH. Lower A1c targets in type 2 diabetes and increased mortality: causal or casual? Am J Med 2013; 126: 1033–1034.
7. Martono DP, Lub R, Lambers Heerspink HJ, Hak E, Wilffert B, Denig P. Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review. Diabet Med 2015; 32: 853–864.
8. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med 2007; 24: 350–358.
9. Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabet Med 2006; 23: 128–133.
10. Nichols GA, Conner C, Brown JB. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin 2010; 26: 2127–2135.
11. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M. Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study. BMC Public Health 2005; 5: 36.
12. Nichols GA, Hillier TA, Javor K, Brown JB. Predictors of glycemic control in insulin-using adults with type 2 diabetes. Diabetes Care 2000; 23: 273–277.
13. de Bruin SR, van Oostrom SH, Drewes HW, de Jong-van Til JT, Baan CA, Struijs JN. Quality of diabetes care in Dutch care groups: no differences between diabetes patients with and without co-morbidity. Int J Integr Care 2013; 13: e057.
14. Raebel MA, Ellis JL, Schroeder EB, Xu S, O'Connor PJ, Segal JB et al. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study. Pharmacoepidemiol Drug Saf 2014; 23: 699–710.
15. Mor A, Berensci K, Svensson E, Nielsen JS, Friborg S, Brandslund I et al. Prescribing Practices and Predictors of Glucose-Lowering Therapy within the First Year in Newly Diagnosed Type 2 Diabetes Patients: Prospective cohort study. Diabet Med 2015; 32: 1546–1554.
16. Fu AZ, Qiu Y, Davies MJ, Radican L, Engel SS. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab 2011; 13: 765–769.
17. McEwen LN, Bilik D, Johnson SL, Halter JB, Karter AJ, Mangione CM et al. Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD). Diabetes Care 2009; 32: 971–976.
18. Vitry AI, Roughead EE, Preiss AK, Ryan P, Ramsay EN, Gilbert AL et al. Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: a cohort study. PLoS One 2010; 5: e14024.
19. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29: 541–549.
20. Thomsen RW, Friborg S, Nielsen JS, Schroll H, Johnsen SP. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2): organization of diabetes care in Denmark and supplementary data sources for data collection among DD2 study participants. Clin Epidemiol 2012; 4: 15–19.
21. Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol 2010; 2: 273–279.
22. Kristensen JK, Drivsholm TB, Carstensen B, Steding-Jensen M, Green A. [Validation of methods to identify known diabetes on the basis of health registers]. Ugeskr Laeger 2007; 169: 1687–1692.
23. Thomsen RW, Baggesen L, Svensson E, Pedersen L, Nørrelund H, Buhl ES et al. Early glycemic control among patients with type 2 diabetes and initial glucose-lowering treatment: A 13-year population-based cohort study. Diabetes Obes Metab 2015; 17: 771–780.
24. Thomsen RW, Baggesen LM, Sogaard M, Pedersen L, Nørrelund H, Buhl ES et al. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes. Diabetologia 2015; 58: 2247–2253.
25. Grann AF, Erichsen R, Nielsen AG, Froslev T, Thomsen RW. Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. Clin Epidemiol 2011; 3: 133–138.
26. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39: 30–33.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.
28. Carstensen B, Kristensen JK, Marcussen MM, Borch-Johnsen K. The National Diabetes Register. Scand J Public Health 2011; 39: 58–61.
29. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011; 11: 83.
30. Danish Endocrine Society. Guidelines for type 2-diabetes. En fælles behandlingsvejledning med enslydende kliniske behandlingsmål [Guidelines for type-2 diabetes. A common treatment guide with common clinical treatment goals]; 2011.